| Trial ID: | L3972 |
| Source ID: | NCT00758069
|
| Associated Drug: |
Sitagliptin Phosphate
|
| Title: |
Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00758069/results
|
| Conditions: |
Diabetes Mellitus, Non-Insulin-Dependent
|
| Interventions: |
DRUG: sitagliptin phosphate|DRUG: Comparator: Placebo|DRUG: Comparator: Sitagliptin
|
| Outcome Measures: |
Primary: Change From Baseline in 24-hour Weighted Mean Plasma Glucose, Change from baseline at Week 4 is defined as 24-hour weighted mean glucose (24hr-WMG) at Week 4 minus 24hr-WMG at Week 0., Baseline and Week 4 | Secondary: Change From Baseline in Plasma Glucose, Change from baseline at Week 4 is defined as fasting plasma glucose at Week 4 minus fasting plasma glucose at Week 0., Baseline and Week 4
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
80
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2005-07-03
|
| Completion Date: |
2006-02-13
|
| Results First Posted: |
2009-09-25
|
| Last Update Posted: |
2017-05-05
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00758069
|
